This looked at patients with transplant-eligible newly diagnosed multiple myeloma, and randomly assigned the patients ... At ...

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

In a real-world study involving patients with standard-risk, newly-diagnosed multiple myeloma (NDMM), there was no significant ... involving whether tandem ASCT improves progression-free survival (PFS ...

Although myeloma is treatable, it is generally not curable, and advanced therapies like blood stem cell transplantation can ...

Multiple myeloma is a type of cancer where plasma ... In a 2017 study, researchers examined the impact of CRAB symptoms on the survival of people with myeloma receiving new types of medications.

The CAR-T cell therapy Carvykti has been shown to be effective among patients outside the confines of a clinical trial.

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

The FDA has granted LBL-034 orphan drug designation for relapsed/refractory multiple myeloma treatment. LBL-034 has received ...

Truist Securities analyst Asthika Goonewardene in an investor note said data for anito-cel—particularly its safety ...

Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...